VEGFA and retinal disorder: In our study, both doses of bumetanide increased sVEGFR-1 secretion by HMRECs in a time-dependent manner, which was correlated with reductions in VEGF and membrane VEGFR-1 expression, confirming its anti-angiogenesis properties and possible therapy applications for proliferative retinopathies.